Catalyst Pharmaceuticals (CPRX) Rating Reiterated by HC Wainwright

Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Friday, The Fly reports.

The analysts wrote, “We raised our PT to $9 from $6 in view of the additional color on the commercial front. We adjusted the launch cost of and lowered the peak penetration from 25% to 18%.””

A number of other equities analysts have also issued reports on CPRX. BidaskClub upgraded Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 24th. Piper Jaffray Companies initiated coverage on Catalyst Pharmaceuticals in a research note on Friday, September 7th. They issued an “overweight” rating and a $5.00 target price for the company. Cantor Fitzgerald initiated coverage on Catalyst Pharmaceuticals in a research note on Thursday, September 20th. They issued an “overweight” rating and a $8.00 target price for the company. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. Finally, Oppenheimer set a $6.00 target price on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $6.35.

Shares of CPRX stock opened at $2.34 on Friday. The firm has a market capitalization of $240.41 million, a P/E ratio of -11.14 and a beta of 2.01. Catalyst Pharmaceuticals has a 1 year low of $2.18 and a 1 year high of $4.18.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.08). As a group, analysts forecast that Catalyst Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

In related news, Director Charles B. O’keeffe acquired 20,000 shares of Catalyst Pharmaceuticals stock in a transaction on Friday, December 14th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $50,000.00. Following the purchase, the director now owns 543,376 shares of the company’s stock, valued at approximately $1,358,440. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 9.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Vanguard Group Inc raised its position in Catalyst Pharmaceuticals by 4.3% in the third quarter. Vanguard Group Inc now owns 4,458,151 shares of the biopharmaceutical company’s stock valued at $16,852,000 after purchasing an additional 185,017 shares during the period. Vanguard Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 4.3% during the third quarter. Vanguard Group Inc. now owns 4,458,151 shares of the biopharmaceutical company’s stock worth $16,852,000 after acquiring an additional 185,017 shares during the period. Teachers Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 12.0% during the third quarter. Teachers Advisors LLC now owns 218,143 shares of the biopharmaceutical company’s stock worth $825,000 after acquiring an additional 23,321 shares during the period. MetLife Investment Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 38.1% during the third quarter. MetLife Investment Advisors LLC now owns 69,540 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 19,191 shares during the period. Finally, Sofinnova Ventures Inc increased its position in shares of Catalyst Pharmaceuticals by 6.9% during the third quarter. Sofinnova Ventures Inc now owns 1,549,552 shares of the biopharmaceutical company’s stock worth $5,858,000 after acquiring an additional 99,595 shares during the period. Institutional investors and hedge funds own 49.61% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Story: Marijuana Stocks

The Fly

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit